![]() |
市場調査レポート
商品コード
1422083
スマートインスリンペンの世界市場の評価:タイプ別、適応症別、使用性別、製品別、接続性別、エンドユーザー別、流通チャネル別、地域別、機会、予測(2017年~2031年)Smart Insulin Pens Market Assessment, By Type, By Indication, By Usability, By Product, By Connectivity, By End-user, By Distribution Channel, By Region, By Opportunities and Forecast, 2017-2031F |
||||||
カスタマイズ可能
|
スマートインスリンペンの世界市場の評価:タイプ別、適応症別、使用性別、製品別、接続性別、エンドユーザー別、流通チャネル別、地域別、機会、予測(2017年~2031年) |
出版日: 2024年02月07日
発行: Market Xcel - Markets and Data
ページ情報: 英文 221 Pages
納期: 3~5営業日
|
世界のスマートインスリンペンの市場規模は、2023年に5,140万米ドル、2031年に1億2,909万米ドルに達し、2024年~2031年の予測期間にCAGRで12.2%の成長が見込まれています。糖尿病の有病率の増加、血糖値管理の向上、患者の利便性向上、継続的な技術の進歩、遠隔医療の重視、意識の高まり、投薬ミスリスクの最小化、潜在的な医療コスト削減などの多数の要因が世界のスマートインスリンペン市場を推進しています。
世界のスマートインスリンペン市場は、糖尿病管理における大きな飛躍を意味します。これらの画期的なデバイスは、糖尿病患者のインスリン投与プロセスに革命をもたらし、精度の向上、利便性の向上、データドリブンな知見を提供し、全体的なウェルビーイングと生活の質を向上させます。世界の糖尿病の流行と、効率的で使いやすい糖尿病管理ツールへのニーズの高まりが、世界のスマートインスリンペン市場の拡大を後押ししています。医療提供者も患者も、インスリン療法を改善し、より効果的な血糖コントロールと糖尿病に伴う長期合併症の減少につながるこれらのデバイスの可能性を認めるようになってきています。
メーカーによる技術の進化とますます精巧化した機能と接続性オプションの導入により、世界のスマートインスリンペン市場は継続的な成長に位置づけられています。スマートインスリンペンは、自動化された正確な用量計算を容易にする技術を備えており、インスリン投与中の人的ミスの可能性を減少させます。これらのデバイスは、頻繁にスマートフォンアプリと無線接続を確立し、ユーザーがインスリン投与履歴、血糖値、その他の重要なデータを追跡することを可能にします。このことは、糖尿病管理の改善と、この慢性疾患を持つ個人の自立性向上への有望な見通しを提示します。
糖尿病のモニタリングとコントロールにスマートな方法を用いることへの意識の高まりが、世界のスマートインスリンペン市場の大きな成長につながっています。糖尿病ケアは、従来の対面診察から、ビデオ診察のような同期型の遠隔医療の手法に移行しつつあり、主に市場の新興企業が提供する非同期型のデジタル医療サービスも増えています。米国ではインスリンペンの利用が過去数十年間で着実に増加しており、1型糖尿病(T1D)と2型糖尿病(T2D)の両方の患者に好まれるインスリン投与方法となっています。インスリンペンは現在、商業保険加入者の間で市場を独占しています。患者がインスリンペンを選ぶ理由は、インスリンバイアルやシリンジ方式に比べて満足度が高く、使いやすいからです。これらのペンは優れた投与精度を提供し、インスリンのアドヒアランス向上につながります。さらに、インスリンペンの使用はHbA1c値を低下させ、高血糖を最小限に抑え、よりよい血糖コントロールを実証しています。初期費用が高いとはいえ、インスリンペンは総医療費の削減につながり、その結果、入院、糖尿病関連の入院、高血糖に関連した医療利用が減少します。
技術革新は、世界のスマートインスリンペン市場の領域を一変させました。これらの開発には、正確な用量計算、即時のスマートフォンデータ統合、ユーザーフレンドリーなインターフェースなどが含まれます。スマートインスリンペンの進化は、人々に健康管理の効率的な手段を提供し、最終的にウェルビーイングの向上と生活の質の改善をもたらします。例えば、2023年3月、自動インスリンデリバリーの先駆者であるDiabeloopは、著名なグローバル医療企業であるNovo Nordiskとの提携を明らかにしました。両社の取り組みは、コネクテッドインスリンペンを組み込んだ相互運用性戦略の推進に焦点を当てています。この契約は、Diabeloopの自己学習型MDI(Multiple Daily Injections)療法用アルゴリズムであるDBL-4pen(TM)と、Novo NordiskのNovoPen(R)6やNovoPen Echo(R)Plusなどの再使用可能なコネクテッドインスリンペンの統合を含みます。
当レポートでは、世界のスマートインスリンペン市場について調査分析し、市場規模と予測、市場力学、主要企業情勢と見通しなどを提供しています。
Global Smart Insulin Pens Market size was valued at USD 51.4 million in 2023, expected to reach USD 129.09 million in 2031 with a CAGR of 12.2% for the forecast period between 2024 and 2031F. Numerous factors are propelling the global smart insulin pens market forward, including the increasing prevalence of diabetes, better management of glycaemic levels, increased patient convenience, ongoing technological progress, a heightened emphasis on telehealth, growing awareness, minimized medication error risk, and potential healthcare cost reductions.
The global smart insulin pens market signifies a significant leap forward in diabetes management. These groundbreaking devices have revolutionized the insulin administration process for people with diabetes, providing them with improved accuracy, convenience, and data-driven insights to improve their overall well-being and quality of life. The escalating global diabetes prevalence and the growing need for efficient and user-friendly diabetes management tools have fuelled the expansion of the global smart insulin pens market. Both healthcare providers and patients are increasingly acknowledging the potential of these devices to improve insulin therapy, leading to more effective glycaemic control and a reduction in the long-term complications associated with diabetes.
With the evolution of technology and the introduction of increasingly sophisticated features and connectivity choices by manufacturers, the global smart insulin pens market is positioned for ongoing growth. Smart insulin pens are furnished with technology that facilitates automated and precise dose calculations, diminishing the potential for human errors during insulin administration. These devices frequently establish wireless connections with smartphone applications, enabling users to track their insulin dosing history, blood glucose levels, and other vital data. This presents a promising outlook for improved diabetes management and increased independence for individuals with this chronic condition.
The increased awareness of using smart methods to monitor and control diabetes has led to significant growth in the global smart insulin pens market. Diabetes care is transitioning from traditional in-person office visits to synchronous telehealth methods, such as video consultations, and increasingly, asynchronous digital healthcare services, primarily provided by emerging players in the market. In the United States, the utilization of insulin pens has witnessed a consistent rise over the past few decades, becoming the preferred mode of insulin delivery for both type 1 diabetes (T1D) and type 2 diabetes (T2D) patients. Insulin pens now dominate the market among commercially insured individuals. Patients opt for insulin pens due to their high satisfaction levels and user-friendliness compared to insulin vial and syringe methods. These pens offer superior dose accuracy, leading to improved insulin adherence. Moreover, insulin pen usage has demonstrated better glycaemic controls, reducing HbA1c levels and minimizing hyperglycemia. Despite initial higher costs, insulin pens translate into lower total healthcare expenses, resulting in fewer hospitalizations, diabetes-related admissions, and instances of hyperglycemia-associated healthcare utilization for users.
Innovations in technology have transformed the realm of the global smart insulin pens market. These developments include precise dose computations, immediate smartphone data integration, and user-friendly interfaces. The evolution of smart insulin pens provides individuals with efficient means of managing their health, ultimately resulting in enhanced well-being and a better quality of life. For example, in March 2023, Diabeloop, a trailblazer in Automated Insulin Delivery, revealed a partnership with Novo Nordisk, a prominent global healthcare firm. Their joint effort focuses on advancing an interoperability strategy incorporating connected insulin pens. The agreement involves the integration of Diabeloop's self-learning algorithm for Multiple Daily Injections (MDI) therapy, DBL-4pen™, with Novo Nordisk's connected and reusable insulin pens, including NovoPen® 6 and NovoPen Echo® Plus.
Government programs focusing on smart insulin pens are pivotal in tackling the worldwide diabetes crisis and improving the well-being of those afflicted with the condition. Governments efforts give a huge boost to global smart insulin pens market. These efforts reflect a forward-looking approach governments took to combat the increasing incidence of diabetes and the escalating need for cutting-edge solutions in diabetes care and management. On January 1, 2023, a notable development occurred as smart insulin pens were incorporated into Medicare Part D by the US government. This means that individuals enrolled in Medicare who rely on smart insulin pens will now have their expenses capped at a maximum of $35 per month for a one-month supply of each approved insulin product. This pivotal inclusion of smart insulin pens in Medicare Part D was mandated under the Affordable Care Act, commonly known as Obamacare. The ACA mandates Medicare to encompass specific categories of diabetes-related supplies, among them being insulin pens. Such initiatives have a large impact on the global smart insulin pens market.
The advent of Bluetooth-enabled smart insulin pens marks a substantial advancement in global smart insulin pens market. These cutting-edge tools amalgamate the precision inherent in conventional insulin pens with the capabilities of Bluetooth connectivity, presenting users with a cohesive and data-centric methodology for managing their insulin therapy. By facilitating immediate data transfer to smartphones and other suitable devices, these smart insulin pens empower individuals managing diabetes to meticulously monitor their insulin doses, oversee blood glucose levels, receive dose guidance, and seamlessly communicate vital health data with healthcare professionals. As an example, in December 2022, Biocorp, a French firm specializing in medical devices and drug delivery systems, unveiled its FDA 510(k) clearance to commercialize the Mallya smart medical device, designed to interface with insulin pens. Mallya, functioning as a smart sensor, seamlessly affixes to insulin pen injectors, effectively transforming them into connected devices via bluetooth.
Disposable smart insulin pens are reshaping diabetes management by merging the simplicity of one-time-use pens with state-of-the-art technology, ultimately influencing the global smart insulin pens market. These compact instruments come pre-filled with insulin and boast smart capabilities like dosage monitoring, reminders, and wireless connectivity. This enables users to administer insulin with accuracy while effortlessly overseeing their treatment progress. The disposability factor removes the necessity for cartridge swaps, streamlining insulin administration and boosting patient adherence. As an example, in November 2021, the French multinational pharmaceutical and healthcare company Sanofi and the Swiss multinational healthcare company Roche established a collaborative effort in France. They united their efforts to promote the utilization of a connected accessory designed for disposable insulin pens. Together, they will create an educational program for healthcare professionals, including physicians and retail pharmacists, focusing on the Biocorp product known as Mallya.
COVID-19 pandemic had a huge impact on the global smart insulin pens market. On one hand, the demand for smart insulin pens surged during the pandemic, primarily driven by the heightened vulnerability of people with diabetes to severe COVID-19 complications, given their increased susceptibility to respiratory infections. This elevated demand was fueled by the urgency for effective diabetes management to reduce hospitalization risks. Conversely, the pandemic disrupted the supply chain for smart insulin pens as production facilities and distribution networks faced closures and shipping challenges, leading to shortages in certain regions. However, despite these short-term setbacks, the long-term outlook for smart insulin pen sales remains positive. COVID-19 underscored the critical importance of effective diabetes management, shedding light on the role smart insulin pens can play in empowering individuals with diabetes to manage their condition proactively and remotely. This heightened awareness is expected to drive sustained growth in the smart insulin pens market.
Amidst the rapidly changing healthcare environment, marked by a strong emphasis on precision, connectivity, and patient-centric care, the global market for smart insulin pens is experiencing a multitude of partnerships and cooperative ventures. These endeavors frequently bring together a diverse array of stakeholders, including pharmaceutical firms, technology enterprises, startups, and healthcare providers, who combine their knowledge and resources with the goal of creating advanced smart insulin pens. These next-generation devices aim not only to enhance insulin delivery precision but also to offer users immediate data insights and the ability to remotely monitor their insulin therapy. In May 2021, Eli Lilly & Co., an American pharmaceutical company, took steps to ensure the compatibility of its forthcoming connected insulin pen system with various daily diabetes management platforms by entering into compatibility agreements with four global providers. These agreements encompass a range of offerings, such as glucose monitoring sensors, digital health solutions, and other resources provided by Roche, Dexcom, Glooko, and myDiabby Healthcare.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.